Ose Immunotherapeutics
Clinical trials sponsored by Ose Immunotherapeutics, explained in plain language.
-
New antibody OSE-279 aims to unleash immune system against tumors
Disease control Recruiting nowThis study tests a new drug called OSE-279 that helps the immune system fight cancer by blocking a protein called PD-1. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: first finding the safest dose, …
Phase: PHASE1, PHASE2 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated May 26, 2026 11:56 UTC
-
New vaccine aims to control lung cancer when immunotherapy fails
Disease control Recruiting nowThis phase 3 trial tests a new treatment called OSE2101 against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has stopped responding to immunotherapy. The study includes 363 adults who have a specific genetic marker (HLA-A2). The goal i…
Phase: PHASE3 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated May 14, 2026 12:01 UTC